AUR-107
/ Dr. Reddy’s, Aurigene
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
April 18, 2026
A Study Evaluating the Safety and Efficacy of AUR107 in Patients With Relapsed Advanced Malignancies (SHAKTI-1)
(clinicaltrials.gov)
- P1 | N=50 | Recruiting | Sponsor: Aurigene Discovery Technologies Limited | Trial primary completion date: Jun 2025 ➔ Jan 2027
First-in-human • Trial primary completion date • Oncology • Solid Tumor
January 31, 2024
A Study Evaluating the Safety and Efficacy of AUR107 in Patients With Relapsed Advanced Malignancies (SHAKTI-1)
(clinicaltrials.gov)
- P1 | N=50 | Recruiting | Sponsor: Aurigene Discovery Technologies Limited | Not yet recruiting ➔ Recruiting
Enrollment open • Oncology • Solid Tumor • MUC16
May 18, 2023
A Study Evaluating the Safety and Efficacy of AUR107 in Patients With Relapsed Advanced Malignancies (SHAKTI-1)
(clinicaltrials.gov)
- P1 | N=50 | Not yet recruiting | Sponsor: Aurigene Discovery Technologies Limited
Metastases • New P1 trial • Oncology • Solid Tumor
1 to 3
Of
3
Go to page
1